English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  50714575    在线人数 :  405
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"nakada"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 1-4 / 4 (共1页)
1 
每页显示[10|25|50]项目

机构 日期 题名 作者
國立成功大學 2024-11 Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri Boku;Narikazu;Omori;Takeshi;Shitara;Kohei;Sakuramoto;Shinichi;Yamaguchi;Kensei;Kato;Ken;Kadowaki;Shigenori;Tsuji;Kunihiro;Ryu;Min-Hee;Oh;Do-Youn;Oh;Cheul, Sang;Rha;Young, Sun;Lee;Keun-Wook;Chung;Ik-Joo;Sym;Jin, Sun;Chen;Li-Tzong;Chen;Jen-Shi;Bai;Li-Yuan;Nakada;Takashi;Hagihara;Shunsuke;Makino;Reina;Nishiyama;Eiji;Kang;Yoon-Koo
國立成功大學 2024-08 Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, pl Kang;Yoon-Koo;Terashima;Masanori;Kim;Young-Woo;Boku;Narikazu;Chung;Cheol, Hyun;Chen;Jen-Shi;Ji;Jiafu;Yeh;Ta-Sen;Chen;Li-Tzong;Ryu;Min-Hee;Kim;Gwang, Jong;Omori;Takeshi;Rha;Young, Sun;Kim;Yong, Tae;Ryu;Won, Keun;Sakuramoto;Shinichi;Nishida;Yasunori;Fukushima;Norimasa;Yamada;Takanobu;Bai;Li-Yuan;Hirashima;Yoshinori;Hagihara;Shunsuke;Nakada;Takashi;Sasako;Mitsuru
國立成功大學 2024 Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, pl Kang;Y, -K.;Terashima;M;Kim;Y, -W.;Boku;N;Chung;H, C.;Chen;J, -S.;Ji;J;Yeh;T, -S.;Chen;L, -T.;Ryu;M, -H.;Kim;J, G.;Omori;T;Rha;S, Y.;Kim;T, Y.;Ryu;K, W.;Sakuramoto;S;Nishida;Y;Fukushima;N;Yamada;T;Bai;L, -Y.;Hirashima;Y;Hagihara;S;Nakada;T;Sasako;M
國立成功大學 2024 Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3�tri Boku;N;Omori;T;Shitara;K;Sakuramoto;S;Yamaguchi;K;Kato;K;Kadowaki;S;Tsuji;K;Ryu;M, -H.;Oh;D, -Y.;Oh;S, C.;Rha;S, Y.;Lee;K, -W.;Chung;I, -J.;Sym;S, J.;Chen;L, -T.;Chen;J, -S.;Bai;L, -Y.;Nakada;T;Hagihara;S;Makino;R;Nishiyama;E;Kang;Y, -K.

显示项目 1-4 / 4 (共1页)
1 
每页显示[10|25|50]项目